KRYS - Krystal Bio unveils Jeune and reveals early-stage data for its lead candidate

Krystal Biotech ([[KRYS]] -2.5%) has launched its wholly-owned subsidiary Jeune, a gene therapy firm targeting rare diseases.Bhushan Hardas a former Chief Medical Officer of Allergan's Dermatology and Medical Aesthetics business has also been appointed as the President of Jeune effective March 29.The company also announced initial safety data from the ongoing Phase 1 trial of Jeune’s lead product candidate, KB301 for treatment of aesthetic skin conditions.KB301 delivers the human COL3A1 gene to increase the formation of normal type III collagen at the site of administration.The evaluation of the safety profile of KB301 was the primary outcome measure of the open-label, dose-ranging study involving adults aged 18-75. And its Secondary outcome measures included COL3A1 transgene expression.Two repeated intradermal injections of KB301 were well tolerated with no apparent safety signals, the company said.No vector shedding was detected in blood, urine, or skin swabs. During a follow-up through day 90 (subjects 1-6; subject 7

For further details see:

Krystal Bio unveils Jeune and reveals early-stage data for its lead candidate